Stockwinners Market Radar for April 19, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:04 EDT Cathie Wood's ARK Investment bought 761K shares of Ginkgo Bioworks today

20:02 EDT thie Wood's ARK Investment bought 333K shares of SomaLogic today

18:31 EDT Rio Tinto reports Q1 Pilbara iron ore production 79.3 Mt, up 11% - Reports Q1 Bauxite production 12.1 Mt, down 11%. Reports Q1 Aluminum production 785 kt, up 7%. Reports Q1 Mined Copper 145 kt, flat y/y. Rio Tinto Chief Executive Jakob Stausholm said: "We continue to make steady progress with our highest ever first quarter shipments achieved in the Pilbara iron ore business. Through the ongoing deployment of our Safe Production System we expect to see a sustainable lift in operating performance across our global portfolio over time, in line with improvements already achieved. We remain focused on disciplined growth in materials the world needs for the energy transition, delivering first sustainable production from the underground mine at Oyu Tolgoi in Mongolia and progressing early works on the Rincon lithium project in Argentina. We advanced the Simandou high grade iron ore project in Guinea with our partners, and entered into an agreement for a joint venture to unlock La Granja in Peru, one of the largest undeveloped copper projects in the world. We continue to take action to strengthen our culture and invest in genuine partnerships, implementing the recommendations of the Everyday Respect report and reaching a new agreement with the Naskapi Nation of Kawawachikamach in Canada. As we progress against our four objectives and strategy, we have a clear long-term pathway to profitable growth and continued attractive shareholder returns."

18:03 EDT Tesla CFO says still at 'maximum pain' on commodity prices in cost structure - CFO Zach Kirkhorn says: ''Generally, as a company, we do expect commodity prices to come down and have a more meaningful impact in the second half of the year."

17:59 EDT PTC director sells $2.72M in common stock - In a regulatory filing, PTC disclosed that its director Blake Moret sold 21.2K shares of common stock on April 18th in a total transaction size of $2.72M.

17:53 EDT Tesla CEO says continuing to build Alpha versions of the Cybertruck for testing - Says "completing the installation of the volume production line at Giga Texas, and we're anticipating having delivery event, a great delivery event probably in Q3."

17:32 EDT IBM says expects $2B in run rate savings by 2024 from cost saving initiatives - Says focus remains on revenue growth and free cash flow. Says expanded gross margin in all segments. Says took $260M workforce rebalancing charge in Q1. Says on track for full-year free cash flow expectation. Says expects $2B in run rate savings by 2024 from cost saving initiatives. Says continues to expect FY23 tax rate in mid to high teen range. Sees Q1 revenue seasonality to be consistent with last year. Says expects one third of operating net income in first half. Comments taken from Q1 earnings conference call.

17:19 EDT Raytheon Technologies awarded $308.46M Navy contract modification - Raytheon was awarded a $308.46M cost-plus-incentive-fee, cost-plus-fixed-fee, and cost-only modification to a previously awarded contract for an option exercise of Combat System engineering, miscellaneous material, and travel supporting Combat System installation, integration, development, testing, correction, maintenance, and modernization of Zumwalt-class mission systems and mission system equipment. Work is expected to be completed by April 2024. In accordance with 10 U.S. Code 2304(c)(1), contract N00024-22-C-5522 for Zumwalt Combat System activation, sustainment, and modernization was not competitively awarded. Raytheon Missiles & Defense is the only responsible source, and no other supplies or services could fulfill the Navy's requirement. The Naval Sea Systems Command, Washington, D.C., is the contracting activity.

17:09 EDT Meta encryption weakens safety and ability to keep child users safe, VGT says - The Virtual Global Taskforce or VGT, is an international alliance of 15 law enforcement agencies to tackle the threat of child sexual abuse, CSA. the alliance said in part: "The VGT first issued its first position statement on end-to-end encryption or E2EE, in 2021. This statement highlighted the devastating impact E2EE can have on law enforcement's ability to identify, pursue and prosecute offenders, when implemented in a way that affects the detection of CSA on industry platforms. It is important to update the VGT position on E2EE in the context of impending design choices by industry. As outlined in our previous statement, there is no doubt that encryption plays an important role in safeguarding privacy, however this must be balanced with the importance of safeguarding children online...The announced implementation of E2EE on META platforms Instagram and Facebook is an example of a purposeful design choice that degrades safety systems and weakens the ability to keep child users safe. META is currently the leading reporter of detected child sexual abuse to NCMEC. The VGT has not yet seen any indication from META that any new safety systems implemented post-E2EE will effectively match or improve their current detection methods...The VGT calls for all industry partners to fully appreciate the impact of implementing system design decisions that result in blindfolding themselves to CSA occurring on their platforms, or reduces their capacity to identify CSA and keep children safe. It is time to confront these concerns and make tangible steps towards possible solutions that we know exist" said the alliance in part. Reference Link

17:05 EDT Nevro names Kevin Thornal CEO - Nevro Corp. announced that Kevin Thornal has been appointed Chief Executive Officer and President of Nevro, effective April 24, 2023, and will also be appointed to the Board of Directors. Mr. Thornal succeeds D. Keith Grossman, who is retiring as Chief Executive Officer and President, also effective April 24, 2023. Mr. Grossman will be appointed to serve as Executive Chairman.

17:02 EDT Via Renewables temporarily suspends quarterly cash dividend - Via Renewables announced that its Board of Directors has elected to temporarily suspend the quarterly cash dividend on its common stock. The decision comes as the company seeks to enhance its financial flexibility and improve its ability to manage market volatility while focusing on strengthening its balance sheet and investing in both organic and inorganic customer growth.

16:53 EDT Las Vegas Sands jumps 5% to $62.25 after Q1 results beat estimates

16:48 EDT Maxar Technologies stockholders approve acquisition by Advent - Maxar Technologies announced that at Maxar's Special Meeting of Stockholders held earlier today, the company's stockholders voted to adopt the Agreement and Plan of Merger, whereby Maxar will be acquired by Advent International, one of the largest and most experienced global private equity investors. Under the terms of the merger agreement, Maxar stockholders will receive $53.00 per share in cash for every share of Maxar common stock they own immediately prior to the effective time of the merger. At the Special Meeting, approximately 99.6% of the shares voted were voted in favor of the transaction, which represented approximately 75.4% of the total outstanding shares of Maxar common stock as of March 15, 2023, the record date for the Special Meeting. "We thank our stockholders for their strong support of this transaction," said General Howell M. Estes, III (USAF Retired), Chair of Maxar's Board of Directors. "We look forward to completing the transaction with Advent and marking the beginning of a new chapter for Maxar's future."

16:40 EDT F5 Networks falls 6% to $128.22 after cutting FY23 guidance

16:35 EDT CNH Industrial divests business activities in Russia for $60M - CNH Industrial announced the divestiture of its business activities in Russia for a total consideration of approximately $60M. This follows the company's announcement in March 2022 that it was suspending supplies to this market. Up until today, the payment of employee salaries and other administrative expenses in Russia have been duly guaranteed. Until March of 2022, the company operated a corporate office in the Moscow region through which it managed the import and distribution of its products in Russia, regional business activities and commercial financing. Its industrial footprint included manufacturing sites for agricultural equipment and implements and construction equipment, and a parts depot. These sites employed approximately 200 employees. For the fiscal year ending 2021, the last full year of operations, the Russian operations generated revenue of approximately $380M, representing 2% of the Company's consolidated revenue in 2021. During the quarter ended March 31, 2022, CNH Industrial recorded charges of $71M related to assets write down, financial receivable allowances, and a valuation allowance against deferred tax assets. The company estimates that it will take additional pre-tax charges of approximately $20M in connection with the divestitures.

16:33 EDT Eneti announces intention to form joint venture company with Transocean - Eneti (NETI) announced the execution of a non-binding memorandum of understanding indicating their intention to form a joint venture company with Transocean (RIG) that will engage in offshore wind foundation installation activities. Transocean has three hundred plus rig-years of experience operating a global fleet of dynamically positioned offshore drilling rigs to a diverse base of energy-producing customers on long-term contracts. Eneti, through Seajacks International, has installed more than 500 wind turbine foundation components at wind farms including Akita & Noshiro, Meerwind, Veja Mate and Moray East. The establishment and operation of the joint venture are subject to definitive agreements which would provide for the conversion of at least two Transocean vessels into floating offshore wind foundation installation platforms, expertise and operational personnel to be provided by both Eneti and Transocean, and the right but not the obligation for each of Transocean and Eneti to invest in the joint venture with additional partners. The vessels, once converted, would be capable of carrying and installing up to six 3,500-ton, 12-meter diameter monopile foundations with state-of-the-art safety and efficiency.

16:30 EDT Actelis Networks announces 1-for-10 reverse stock split - Actelis Networks announced that on April 18 the Company filed a Certificate of Amendment to the Twenty Fourth Amended and Restated Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware to affect a 1-for-10 reverse stock split of the shares of the Company's common stock . The Common Stock began trading on a Reverse Stock Split-adjusted basis on the Nasdaq Capital Market on April 19.The Company undertook the Reverse Stock Split with the objective of meeting the minimum $1.00 per ordinary share bid requirement under Nasdaq Listing Rule 5550(a)(2) for maintaining the listing of the shares of the Common Stock on the Nasdaq Global Capital Market.

16:28 EDT Fusion Pharmaceuticals' FPI-2059 shows tumor growth inhibition - Fusion Pharmaceuticals announced the presentation of preclinical data that provide further support of its clinical stage FPI-2059, a neurotensin receptor 1 - NTSR1 - targeted alpha therapy and additional preclinical development programs. Data from preclinical studies of FPI-2059 demonstrates robust FPI-2059 tumor uptake and dose-dependent tumor growth inhibition and therapeutic efficacy in a preclinical colorectal tumor model. These data provide further evidence supporting the clinical development of FPI-2059, which is currently being evaluated in a Phase 1 study for the treatment of solid tumors expressing NTSR1. Data from additional preclinical studies highlight the potential of tumor endothelial marker 1 - TEM-1 - and epidermal growth factor receptor variant 3 as targets for actinium-225 labelled TATs.

16:26 EDT Costco increases quarterly cash dividend to $1.02 per share - Costco announced that its board has declared a quarterly cash dividend on Costco common stock and approved a quarterly increase from 90c to $1.02 per share, $4.08 on an annualized basis. The dividend is payable May 19 to shareholders of record at the close of business on May 5.

16:21 EDT Discover raises quarterly dividend to 70c per share from 60c - The Board of Directors increased the quarterly dividend from $0.60 to $0.70 per share, and declared a quarterly cash dividend of $0.70 per share of common stock payable on June 8, 2023, to holders of record at the close of business on May 25, 2023.

16:19 EDT Crown PropTech Acquisitions receives notice of late filing from NYSE - Crown PropTech Acquisitions announced that it received a notice from the New York Stock Exchange on April 18, 2023 indicating that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Annual Report on Form 10-K for the year ended December 31 with the Securities and Exchange Commission. The NYSE informed the Company that, under NYSE rules, the Company will have six months from April 17, 2023 to file the Form 10-K with the SEC. The Company can regain compliance with the NYSE listing standards at any time prior to that date by filing its Form 10-K. If the Company fails to file the Form 10-K before the NYSE's compliance deadline, the NYSE may grant, at its sole discretion, an extension of up to six additional months for the Company to regain compliance, depending on the specific circumstances. The notice from the NYSE also notes that the NYSE may nevertheless commence delisting proceedings at any time if it deems that the circumstances warrant.

16:17 EDT Genco Shipping CFO Apostolos Zafolias to leave - Genco Shipping announced that Apostolos Zafolias, the company's CFO and executive VP, finance, will be leaving the company to pursue an opportunity outside of the maritime industry. Zafolias, who has been with Genco since 2005 and served as its CFO since 2014, is anticipated to serve in his current roles at Genco through June 15 and then as a consultant through December 31 to assist with an orderly transition.

16:16 EDT The Hanover sees Q1 catastrophe losses about $175M - The Hanover Insurance Group announced a preliminary estimate for first quarter catastrophe losses of approximately $175M, before taxes, or 12.7 points of net earned premium. First quarter catastrophe losses stemmed from over 20 weather events, including severe freeze events in the Northeast and Midwest in February, and widespread wind and tornadic activity that impacted nearly half of the U.S. in mid-to-late March.

16:14 EDT Alcoa backs 2023 alumina, aluminum shipment guidance - The Company "expects 2023 total alumina and aluminum shipments to remain unchanged between 12.7 and 12.9 million metric tons, and between 2.5 and 2.6 million metric tons, respectively. As a result of a prolonged annual mine plan approvals process at its Huntly mine, which supplies the Kwinana and Pinjarra refineries, Alcoa began mining lower bauxite grades in April 2023 from areas already permitted under existing approvals. The reduction in grade will extend the ore supply and provide more time to work through the approvals process. The Company expects lower sequential Alumina Segment Adjusted EBITDA of approximately $55 million in the second quarter related to operating the Kwinana and Pinjarra refineries at the lower bauxite grade, which impacts the refineries with higher usages of caustic, energy, and bauxite and results in lower alumina output. Additionally, the Company expects net unfavorable $10 million impacts as seasonal maintenance and costs associated with the Alumar refinery conveyance system recovery are partially offset by improvements in raw materials and energy prices. For the second quarter 2023, the Aluminum Segment Adjusted EBITDA is expected to improve by $30 million on favorable raw materials, volume and lower production costs, partially offset by changes in value added premiums. In addition, the Company expects $5 million to $10 million in unfavorable impacts associated with the Portland smelter partial curtailment. Other expense is expected to be favorable by approximately $30 million sequentially primarily due to the absence of a one-time charge recorded in the first quarter."

16:13 EDT Argo shareholders approve proposed merger with Brookfield Reinsurance - Argo Group International (ARGO) announced that Argo shareholders voted to approve an agreement for Brookfield Reinsurance Ltd. (BNRE) to acquire Argo in an all-cash transaction valued at approximately $1.1B. The Merger remains subject to other customary closing conditions, including receipt of required regulatory approvals. Argo and Brookfield Reinsurance expect to complete the Merger in the second half of 2023.

16:12 EDT Alcoa reports Q1 adjusted EBITDA $240M vs. $1.07B last year - The company states: "Adjusted EBITDA excluding special items was $240M, a $211M sequential increase due primarily to higher sequential prices for aluminum and alumina, lower energy costs in Europe, and the nonrecurrence of a $25 million charge to establish an asset retirement obligation at the Alumar refinery in Brazil in the fourth quarter 2022."

16:09 EDT Las Vegas Sands CEO says robust recovery in travel and tourism spending underway - "While travel restrictions and reduced visitation continued to impact our financial performance during the quarter, a robust recovery in travel and tourism spending across our markets is now underway. We remain enthusiastic about the opportunity to welcome more guests back to our properties throughout 2023 and in the years ahead," said RobertGoldstein, chairman and CEO. "In Singapore, we were pleased to see the ongoing recovery at Marina Bay Sands progress during the quarter, with the property again delivering outstanding levels of performance in both mass gaming and tenant sales. We remain energized by the opportunity to introduce our new suite product to more customers as airlift capacity continues to improve and the recovery in travel and tourism spending from China and the wider region continues. In Macao, we were pleased to see the ongoing recovery now underway in all gaming and non-gaming segments accelerate during the quarter. We remain deeply enthusiastic about the opportunity to continue our investments to enhance Macao's tourism appeal to travelers from throughout the region, including to foreign visitors to Macao. Our decades-long commitment to making investments that enhance the business and leisure tourism appeal of Macao and support its development as a world center of business and leisure tourism positions us exceedingly well to deliver strong growth as visitation to the market increases and the recovery in travel and tourism spending proceeds. Looking ahead, our resolute commitment to making industry-leading investments in our team members, our communities and our market-leading Integrated Resort property portfolio positions us exceptionally well to deliver strong growth in the years ahead. Our financial strength supports our ongoing investment and capital expenditure programs in both Macao and Singapore, as well as our pursuit of growth opportunities in new markets."

16:06 EDT Tesla says Cybertruck on track to begin production later this year - Tesla said: "We have sufficient liquidity to fund our product roadmap, long-term capacity expansion plans and other expenses. Furthermore, we will manage the business such that we maintain a strong balance sheet during this uncertain period. While we continue to execute on innovations to reduce the cost of manufacturing and operations, over time, we expect our hardware-related profits to be accompanied with an acceleration of software-related profits. We continue to believe that our operating margin will remain among the highest in the industry. Cybertruck remains on track to begin production later this year at Gigafactory Texas. In addition, we continue to make progress on our next generation platform."

16:06 EDT Tesla backs 2023 volume view of 'around 1.8M cars' - Tesla said in its quarterly update letter: "We are planning to grow production as quickly as possible in alignment with the 50% CAGR target we began guiding to in early 2021. In some years we may grow faster and some we may grow slower, depending on a number of factors. For 2023, we expect to remain ahead of the long-term 50% CAGR with around 1.8 million cars for the year."

16:05 EDT Tesla reports Q1-end cash increased to $22.4B - Tesla said: "Quarter-end cash, cash equivalents and investments increased sequentially by $217M to $22.4B in Q1, driven mainly by free cash flow of $441M, partially offset by other financing activities, including debt repayments."

15:53 EDT Microsoft removes Twitter from advertising platform - Microsoft (MSFT) said that Twitter (TWTR) is being removed from its business-to-business advertising plan next next week. The software giant said that, starting on April 25, 2023, Smart Campaigns with Multi-platform will no longer support Twitter. Reference Link

15:37 EDT Square Enix, Elixir Games partner to boost web3 gaming - Elixir Games, a web3 gaming distribution platform, has announced the formation of a strategic partnership with Square Enix focused on generating visibility and adoption of web3 games among traditional gamers. The partnership will allow millions of gamers to explore quality web3 games through a platform that hides web3 technology under the hood and offers a simple seamless experience to the traditional gamer. Square Enix, who together with Sino Global Capital co-led Elixir Games' last fundraising seed round in December 2022, has put in place a strong web3 gaming investment strategy, with a belief that blockchain games will transition into a new stage of growth in 2023, Elixir notes.

14:09 EDT Snap says My AI rolling out to Snapchatters globally with new features - Snap announced that "My AI is rolling out to Snapchatters globally, now with brand new features," including "Personalize My AI," "Bring My AI into Conversations with Friends," "Snapchat Recommendations," "Share Snaps with My AI," and "Watch It Snap You Back." The company added that, "My AI is far from perfect, but we've made a lot of progress. For example, 99.5% percent of My AI responses conform to our community guidelines, and since launch, we've worked to improve by: Programming My AI to adhere to our community guidelines to help protect against responses that could be inappropriate or harmful. Implementing a new age signal using a Snapchatter's birthdate, so the chatbot will consistently take their age into consideration. Adding additional moderation technology, which will allow us to assess the severity of potentially harmful content and temporarily restrict Snapchatters' access to My AI if they misuse the service. Preparing to incorporate My AI into our in-app parental tools, Family Center, which will allow caregivers to see if their teens are chatting with My AI and how often."Reference Link

13:43 EDT Apple CEO says company shares 'vision of positive impact' of tech with India PM - Apple CEO Tim Cook thanked India's Prime Minister Narendra Modi for the "warm welcome" in a tweet after Cook met with Modi in the South Asian country. "We share your vision of the positive impact technology can make on India's future - from education and developers to manufacturing and the environment, we're committed to growing and investing across the country," Cook tweeted. Reference Link

13:40 EDT Snap announces new programs, features for creators - Snap has announced "new programs that help creators build sustainable businesses and introduced new tools to grow and engage with their audience across Stories and Spotlight." Regarding monetization programs, the company said that, "Now, creators who have at least 50,000 followers, 25 million monthly Snap views, and post at least 10 Stories a month may be eligible to join our Stories revenue share program... Our Spotlight reward program is one of the ways we continue to support our community of aspiring and emerging creators as they turn content creation into a career. We are increasing the total rewards available to reward creators for making the top Spotlight Snaps." On Public Stories, Snap says that starting today, "Snapchatters aged 18 or older will be able to post their own Public Story with a simple tap. Open the camera, create a Snap, and choose to share it with friends or add it to your Public Story, all from the same account... Our new scheduling feature gives creators more control and allows them to post to their Story whenever, wherever. Creators can also save a Snap to their new Public Profile and get access to content performance insights and Story Replies." The company is also expanding creator content on Snapchat, "bringing creator content to new surfaces across Snapchat like Snap Map and are making it easier to discover creators across Stories and Spotlight. Creators helping our community discover the next "can't miss" restaurant can expand their reach by simply tagging locations in their Spotlight Snaps. With place tags, their videos will appear on place profiles on the Snap Map, where more than 300 million Snapchatters go each month for great local recommendations." Reference Link

13:07 EDT North American rail traffic down 3.6% for the week ending April 15 - The Association of American Railroads, AAR reported U.S. rail traffic for the week ending April 15. For this week, total U.S. weekly rail traffic was 468,197 carloads and intermodal units, down 4.4%t compared with the same week last year. Total carloads for the week ending April 15 were 234,066 carloads, up 5.8% compared with the same week in 2022, while U.S. weekly intermodal volume was 234,131 containers and trailers, down 12.8% compared to 2022. Eight of the 10 carload commodity groups posted an increase compared with the same week in 2022. They included nonmetallic minerals, up 3,445 carloads, to 33,677; motor vehicles and parts, up 2,408 carloads, to 14,871; and metallic ores and metals, up 2,195 carloads, to 22,835. Commodity groups that posted decreases compared with the same week in 2022 were miscellaneous carloads, down 668 carloads, to 8,714; and forest products, down 272 carloads, to 9,311. North American rail volume for the week ending April 15, on 12 reporting U.S., Canadian and Mexican railroads totaled 339,933 carloads, up 6% compared with the same week last year, and 311,134 intermodal units, down 12.3% compared with last year. Total combined weekly rail traffic in North America was 651,067 carloads and intermodal units, down 3.6%. North American rail volume for the first 15 weeks of 2023 was 9,601,378 carloads and intermodal units, down 3.9% compared with 2022. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific Kansas City (CP), Kansas City Southern (KSU), Norfolk Southern (NSC), Union Pacific (UNP), Trinity Industries (TRN), Greenbrier (GBX). FreightCar America (RAIL) and Wabtec (WAB).

12:22 EDT Jupiter Wellness Acquisition Corp trading resumes

12:13 EDT Amazon to distribute Fox's local news content across devices - Fox Television Stations and Amazon have jointly announced they are teaming up to distribute Fox's local news content across Amazon's devices. Effective immediately, Fox will provide seventeen 24/7 local, free, ad-supported television channels, one from each market covered by the Fox Television Stations, through the Amazon News app on Fire TV and Alexa on Echo Show devices. Reference Link

12:00 EDT XPeng falls -12.0% - XPeng is down -12.0%, or -$1.35 to $9.93.

12:00 EDT ProShares UltraShort Bloomberg Natural Gas rises 8.1% - ProShares UltraShort Bloomberg Natural Gas is up 8.1%, or $5.14 to $68.32.

12:00 EDT Western Alliance rises 15.5% - Western Alliance is up 15.5%, or $5.05 to $37.56.

11:33 EDT March 2023 video game spending in U.S. fell 5% y/y, says Circana - Circana analyst Mat Piscatella said that U.S. consumer spending on video game content, hardware and accessories totaled $4.6B in March, a 5% decline when compared to a year ago. Year-to-date consumer spending fell 1% when compared to the same period in 2022, to $13.6B. Sony's (SONY) PlayStation 5 lifted hardware spending in March. However this growth was offset by a decline in content spending, where increases in non-mobile subscription as well as digital add-on console content were offset by lower spend across premium games, PC add-on content and mobile. Video game hardware spending increased 10% when compared to March 2022, reaching $566M. This is the second highest video game hardware spend for a March month in U.S. history, trailing only the $680M reached in March 2021. Growth in PlayStation 5 hardware spending once again drove the March hardware gains. PlayStation 5 was the best-selling hardware platform in units and dollars for both March as well as 2023 year-to-date. PlayStation 5 hardware unit sales have now surpassed those of PlayStation 4 on a time-aligned basis. Year-to-date hardware spending is now 21% higher when compared to the same period in 2022, at $1.5B. Other notable video game hardware makers include Microsoft (MSFT) and Nintendo (NTDOY). Reference Link

11:29 EDT Freedom Holding down 2% after Citron says 'has FTX written all over it' - Shares of Freedom Holding are lower after Citron Research issued a short report in which the firm states: "We all look back at FTX and question how it happened... This story only scratches the surface of the numerous concerns surrounding the accuracy of Freedom Holdings' financial reports and future projections. There are still many unanswered questions about the divestiture of their Russian arm and whether the transaction is legitimate... While the issue of violating war sanctions is discussed in this report, the flaws and misrepresentation of their business are not adequately addressed. Ultimately, if FFIN is treated as a subsidiary rather than a related party, FRHC would be required to restate all financials and would be in violation of Russian War Sanctions, which could result in delisting. These are critical issues that require further investigation and attention from regulators and investors."

11:23 EDT GE Aerospace, Lockheed announce F-35 avionics and power services agreement - GE Aerospace (GE) announced it has signed an agreement with Lockheed Martin (LMT) to support avionics and electrical power systems on the F-35 globally. "The four-year agreement entails maintenance, repair, and overhaul for GE Aerospace systems on the F-35 Lightning II aircraft. GE Aerospace will service the F-35 systems at their repair and maintenance locations in California, Georgia, and Utah as well as GE sites at Grand Rapids, Michigan, Long Island, New York and Cheltenham, United Kingdom," GE stated.

11:17 EDT Tourlite calls on GasLog Partners board to reconsider $8.65 per share offer - Tourlite Capital Management sent a letter to the Board of Directors of Gaslog Partners, which read in part: "We are writing on behalf of Tourlite Capital Management, LP and our affiliates. Tourlite is a shareholder of GasLog Partners LP. We have deep conviction in the extraordinary value of GasLog and its assets. We urge the Board of Directors and the Board's Conflicts Committee to reconsider the current price offered for GasLog, which significantly underestimates the fair value of the assets. We believe the current offer of $8.65 per share is a disservice to shareholders. Tourlite estimates a fair value between $10.00 - $12.00 per share, a ~16% - 39% premium to the current offer. We urge shareholders to vote against the current offer...Based on our detailed analysis and our estimate of fair value, Tourlite plans to vote AGAINST the current bid of $8.65 and urge fellow shareholders to do the same.As a next step, we look forward to discussing our recommendations with you over the next several weeks. Our goal is to align the interests of all parties, and Tourlite would welcome the opportunity to engage closely with the Board of Directors and management throughout this process. Tourlite greatly appreciates the Board's time in considering our thoughts and analysis. We strongly believe reconsidering the current offer is in the best interest of the Company's shareholders. For full disclosure, Tourlite and its affiliates own shares of GasLog and GasLog Preferred and stand to benefit if the share price increases."

11:04 EDT Coca-Cola enters licensing agreement with Frutura - Frutura has signed a licensing agreement with The Coca-Cola Company. The deal allows Frutura to use Minute Maid and Simply brands, which will be exclusively deployed by Frutura's Dayka & Hacket. The Simply brand is entering the produce category as Simply Select. Initially: Simply Select will be used on D&H fresh citrus in the United States; Minute Maid will be used on D&H grapes in the United States, and: Minute Maid will be used on D&H fresh citrus and grapes in Japan. Products bearing Coca-Cola's Minute Maid and Simply Select imagery will be integrated with D&H's existing brand portfolio and will begin appearing at retail in Q2.

11:02 EDT Sonoco Products raises quarterly dividend 4% to 51c per share - The Board of Directors of Sonoco increased its quarterly common stock dividend by approximately 4 percent to 51c per share from the previous quarterly distribution of 49c per share. This new dividend will be paid on June 9, 2023, to shareholders of record as of May 10, 2023. With this increase, Sonoco's annualized dividend payout moves to $2.04 per share from $1.96 per share. Future quarterly declarations and the establishment of future record and payment dates are subject to final determination by Sonoco's Board of Directors.

10:58 EDT TOP Financial Group Ltd trading resumes

10:47 EDT Cuentas enters operating agreement to develop 360 unit apartment complex - Cuentas is adding to its growing affordable real estate portfolio, signing an operating agreement to develop a 360 apartment complex near Tampa, Florida, to be called "Arden By Cuentas Casa". The project will be managed by Brooksville Development Partners and will be built on a 21.8 acre parcel of land in Brooksville Florida, a suburb of Tampa and a short drive from Clearwater beaches. Cuentas initially invested in the property purchase and is the majority shareholder in the project. Arden is the second project in the Cuentas Casa initiative, delivering on management's goal of creating affordable real estate that is also sustainable real estate, and utilizing the Company's growing financial toolset to make home rental available to those who have previously been left out of the system. The Development will be utilizing the patented, leading edge construction technology from Renco USA, featuring Renco's MCFR Construction System which provides cost efficiency, reduced build time, and provides sustainable benefits. Rather than relying on government subsidy, management is focusing on combining the cost benefits of innovative, patented construction techniques with the alternative credit and financial management tools in the Cuentas platform to deliver a superior product for rental at an unexpectedly affordable price. Cuentas is investing $2M out of the contracted $5.1M price to complete acquisition of the property, which is expected to close next week. Cuentas has the exclusive rights to offer additional Cuentas Services to potential renters. When completed, the property will have over 346,000 square feet of rentable space.

10:36 EDT United Airlines: 'Can't run the airline like it's 2019'

10:35 EDT United Airlines: Macro risks higher today than even a few months ago

10:28 EDT Waze on Google built-in now available on Volvo, Polestar 2 cars - Waze is now available on all Volvo (VLVLY) and Polestar 2 (PSNY) cars with Google (GOOGL) built-in, directly through the car's infotainment system. The company said that, "Now Volvo and Polestar drivers can access Waze's real-time routing, navigation, alerts, settings, preferences and saved places. After a one-time setup, drivers will enjoy a bigger, bolder navigation display - right at eye level - without ever having to use their phones." Waze built-in, a version of Waze for in-car infotainment systems, "eliminates phone-related hassles and distractions" thanks to its embedded and wireless capabilities. Waze developed and tested the embedded app with an emulator and Volvo and Polestar 2 cars to deliver the best possible experience before launching in customer cars. Reference Link

10:06 EDT Werewolf Therapeutics publishes preclinical data on mWTX-330 - Werewolf Therapeutics announced the publication in Cancer Immunology Research Online First of preclinical data for mWTX-330, a systemically delivered Interleukin-12 INDUKINE molecule. The article, entitled "mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity," includes preclinical data that demonstrates that mWTX-330 delivers IL-12 selectively to the tumor microenvironment, where it stimulates a potent anti-tumor immune response. Other key findings and data outlined in the article include: mWTX-330 treatment generates a robust, cleavage-dependent anti-tumor immune response in multiple syngeneic tumor models and is well tolerated. mWTX-330 delivery expands the therapeutic window of the IL-12 cytokine. mWTX-330 treatment activates various tumor-infiltrating lymphocyte populations in the MC38 mouse model and results in the transcriptional reprogramming of the tumor microenvironment and the subsequent activation of various tumor-infiltrating effector-cell populations. mWTX-330 treatment expands unique T-cell receptor clones and increases TCR clonality in the tumor microenvironment. mWTX-330 treatment substantially increases mitochondrial activity in tumor infiltrating CD8+ T cells and NK Cells while reducing signs of exhaustion on CD8+ T cells. The fully human WTX-330 INDUKINE molecule is preferentially activated by primary human tumors. Werewolf is currently recruiting patients for a first-in-human, multi-center, open-label Phase 1 clinical trial that will evaluate WTX-330 in patients with advanced or metastatic solid tumors or lymphoma resistant to checkpoint inhibitors or for which checkpoint inhibitors are not approved.

10:01 EDT BAE Systems awarded $8.3M contract by DARPA to develop advanced autonomy - The U.S. Defense Advanced Research Projects Agency has awarded BAE Systems an $8.3 million contract to develop an advanced autonomy system to speed operational planning under the Strategic Chaos Engine for Planning, Tactics, Experimentation, and Resiliency program Under the terms of the Phase 1 contract, BAE Systems' FAST Labs research and development organization will provide the machine-learning backed system and execute tests to demonstrate the approach. In this program, the BAE Systems team will collaborate with Professor Igor Mezic and AIMdyn, a small woman-owned business, and with Professor Joao Hespanha, an expert in control and multi-agent systems.

10:00 EDT Olo falls -7.6% - Olo is down -7.6%, or -67c to $8.13.

10:00 EDT XPeng falls -9.4% - XPeng is down -9.4%, or -$1.06 to $10.22.

10:00 EDT USD Partners rises 9.6% - USD Partners is up 9.6%, or 36c to $4.15.

09:58 EDT Knightscope renews security robot contract with Westland Real Estate Group - Knightscope shipped multiple Autonomous Security Robots over the last 30 days, representing approximately $258,000 of annualized revenue. ASRs are arriving in California, Florida, New York, Washington and Washington DC. Also contributing to the backlog reduction were shipments of numerous blue light emergency communication systems, representing approximately $417,000 in revenue. In total, this contributed to the reduction of the Company's $5M backlog by more than 12%. Westland Real Estate Group, which operates over 65 residential communities on the west coast, renewed its contract to use a Knightscope K5 ASR to patrol one of its Las Vegas residential communities in an area known to have high crime rates.

09:51 EDT Nano Dimension says Stratasys news release misleads shareholders - Nano Dimension (NNDM) responded to the statement released by Stratasys (SSYS) on April 18th, 2023: "It is disappointing that Stratasys has resorted to sowing misinformation and falsehoods in its rebuff of Nano Dimension's acquisition offer that would provide immediate and certain cash payment at a compelling premium to share price to Stratasys shareholders. COURT RULED: NANO CAN COMPLETE THE STRATASYS ACQUISITION: These claims are nothing more than a desperate attempt to mask the Board's clear entrenchment and efforts to mislead shareholders. The facts speak for themselves. The Israeli court's ruling vindicated Nano Dimension's position that its Board of Directors has the full authority to continue to lead and govern the Company as they have been, including as it relates to Nano Dimension's proposed acquisition of Stratasys. Clearly the Stratasys' board members are trying to exploit the court decision in order to interfere with the Company's intention to initiate a Special Tender Offer to the shareholders of Stratasys in order to preserve their position as board members. In its ruling from April 16th, 2023, the district court in Lod, Israel, rejected Murchinson's motion and stated explicitly that Murchinson's motion 'whereby the Company will not be allowed to take any action that is not in the ordinary course of business... will harm the Company in an excessive way' and explicitly mentioned the completion of the Stratasys transaction as an example where such a restriction cannot be accepted. The Company has a clear and full authority to take actions that are not in the ordinary course of business including the Stratasys transaction and any claim made to the contrary by Stratasys is false and misleading. MURCHINSON & ANSON'S ILLEGAL ACTIONS: The Company intends to appeal against the appointment of the two observers. The fact remains that Murchinson and Anson's sham vote was illegitimate and invalid. Nano Dimension is appealing to the Israeli Supreme Court to block the Court's temporary appointment of the two Murchinson observers, which is not for the best interest of the Company and its shareholders; those observers have one goal - to interfere with the Company's business affairs and transactions and as a result harm the interests of the Company's shareholders. Murchinson's aggressive action to call an illegal shareholders meeting should not be rewarded with an appointment of two observers, where other shareholders do not enjoy the same right. Murchinson and Anson's Invalid Meeting Results Demonstrate Nano Dimension Shareholders' Lack of Interest in their Agenda: Over 90% of Nano Dimension shares, excluding those owned by Murchinson or Anson, either voted against Murchinson's nominees or took no action. In other words, excluding their own shares, Murchinson and Anson garnered support representing less than 9.5% of shares voted. The embarrassingly low voter turnout is proof that Nano Dimension shareholders will not be coerced by an actor who the Company believes is solely interested in making a quick profit at the expense of substantial potential long-term value for other shareholders. IT'S TIME TO ALLOW STRATASYS SHAREHOLDERS TO HAVE THEIR SAY: Nano Dimension will continue to proceed towards acquiring Stratasys as it prepares for an all-cash special tender offer at $18.00 per share, which would allow shareholders to choose for themselves and receive a significant and immediate premium for their shares."

09:47 EDT Mytheresa falls -7.1% - Mytheresa is down -7.1%, or -51c to $6.72.

09:47 EDT XPeng falls -7.3% - XPeng is down -7.3%, or -82c to $10.46.

09:47 EDT Metropolitan Bank rises 13.8% - Metropolitan Bank is up 13.8%, or $4.24 to $35.04.

09:46 EDT Shift4 Payments down 3% in early trading after Blue Orca short report

09:41 EDT Roku announces new Primetime Reach Guarantee - The company said, "Reach more TV households in primetime than you can find on the average program airing on a top-five cable network* - that's a first from Roku, Inc. with its new Primetime Reach Guarantee ahead of the TV Upfronts. Marketers have long valued TV advertising for its ability to reach large audiences quickly. Today, brands are shifting advertising spend to TV streaming to follow the consumer. According to eMarketer, the daily average time spent with TV streaming devices by U.S. adults increased by 25 percent in the past two years. However, advertisers have lacked assurance that their TV streaming campaigns will accumulate audiences quickly during key brand moments, such as holiday shopping weekends and big product launches. Now, Primetime Reach Guarantee brings a key benefit of cable advertising to TV streaming advertising. To get started, marketers choose a primetime date. Roku then prioritizes delivery to unique households across The Roku Channel and the additional top 100 channels on the platform. In a pilot with one financial services brand, Roku reached more TV households during the one-day flight during primetime (8:00-11:00 PM locally) than an average program on a top-five cable network. Total household reach was 15% greater with Roku, helping the brand reach more prospective account holders during a key moment."

09:21 EDT Bimbo Ventures makes minority investment in Olyra Foods - Olyra Foods announces Bimbo Ventures, the venture capital arm of Grupo Bimbo, has made a minority investment in the company. Grupo Bimbo S.A.B de C.V., the world's largest baking company with operations in 34 countries, is known for its category leading brands, innovative products, freshness and quality. The funding will help Olyra Foods further expand its presence in retail and on-line marketplaces.

09:18 EDT DSS plans to distribute stock of Sharing Services Global to shareholders - DSS announced that the Company plans to distribute to its stockholders common stock of Sharing Services Global Corporation that is beneficially held by DSS, directly and through its subsidiary, Decentralized Sharing Systems, DSSI. Sharing Services is a diversified direct marketing company that is currently listed on the OTC and is in the process of up-listing to Nasdaq. As a major shareholder in Sharing Services, DSS is focused on identifying opportunities that will foster the long-term growth of SHRG and provide long-term benefit to its shareholders. DSS, together with its subsidiary DSSI, plan to distribute approximately 280 million shares, which represents over $5 million at the current market value of Sharing Services' common stock beneficially held by DSS and DSSI in a distribution to holders of DSS common stock, par value $0.02 per share as of April 28, 2023. Immediately prior to the Distribution, DSS, together with its subsidiary DSSI, will beneficially hold 81.1% of the issued and outstanding shares of SHRG Common Stock. Upon completion of the Distribution, DSS and its subsidiary, DSSI, will retain an ownership interest of approximately 7% in Sharing Services Global Corporation.

09:17 EDT Molekule announces dismissal of trademark infringement complaint - Molekule Group (MKUL) announced that a civil complaint previously filed against the Company has been favorably resolved with all claims against the Company dismissed by the Court with prejudice. The complaint was filed on August 11, 2022, in the U.S. District Court for the Southern District of New York, Case No. 7:22-cv-06842- PMH by Sterilumen, a wholly-owned subsidiary of Applied UV (AUVI). Sterilumen's complaint sought $20 million dollars in damages against the Company for, among other claims, alleged trademark infringement and unfair business competition. In response, the Company filed counterclaims contesting the validity of Sterilumen's trademark rights and seeking money damages for fraudulent registration thereof. By its Order dated March 13, 2023, the Court agreed with Molekule's position and ruled the Action dismissed with prejudice. Molekule subsequently reached a favorable agreement with Sterilumen to forgo pursuing Molekule's Counterclaims, among other things. As a result, Sterilumen's claims against Molekule's trademarks are permanently barred and Sterilumen has waived its right to appeal the Order. The Company achieved this outcome without having to compensate Sterilumen in any manner, and its legal expenses were covered by an insurance policy.

09:15 EDT Vincerx Pharma presents preclinical data on VIP924 - Vincerx Pharma presented a poster of VIP924 preclinical data at the 2023 American Association for Cancer Research, AACR, Annual Meeting. VIP716 is a novel highly potent and selective kinesin spindle protein inhibitor, which has been modified with a hydrophilic CellTrapper moiety to reduce membrane permeability without having a negative impact on efficient target binding. This modification allows for intracellular accumulation of VIP716 in CXCR5+ tumor cells, providing greater efficacy, and prevents cellular penetration into healthy tissues, reducing toxicity. "We are thrilled to continue advancing our bioconjugation platform with our newest ADC, VIP924," said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. "At AACR, VIP924 showed meaningful preclinical activity in a panel of lymphoma cell lines and in cell line-derived and patient-derived lymphoma mouse models. Most notably, mouse models implanted with tumor cells from lymphoma patients demonstrated significant tumor growth inhibition and prolonged survival after VIP924 treatment. Showing activity in mouse models implanted with tumor cells from patients, also known as PDX models, is particularly meaningful because PDX models are more representative of the complexity of human cancer than results seen with cell lines."

09:13 EDT Abbott sees Q2 Covid-19 testing sales about $200M

09:13 EDT Onconova announces presentation of new preclinical data on narazaciclib - Onconova Therapeutics announced new preclinical data on narazaciclib in two poster presentations at the American Association for Cancer Research, AACR, Annual Meeting. Poster 5987: Differential targets engaged by narazaciclib in comparison to the approved CDK 4/6 inhibitors contribute to enhanced inhibition of tumor cell growth. Featured in this poster are data characterizing narazaciclib's mechanism of action and activity in preclinical cancer models. Results showed that, in addition to inhibiting kinases such as CDK 4/6, narazaciclib treatment led to the degradation of other kinases not targeted by the FDA-approved CDK 4/6 inhibitor palbociclib. These kinases included BUB1, the overexpression of which was shown to be associated with poor prognosis in breast cancer and uterine corpus endometrial carcinomas. Poster 5974: Synergistic activity of the CDK 4/6 antagonist narazaciclib with irreversible BTK inhibition in ibrutinib-resistant mantle cell lymphoma. Data featured in this poster demonstrate narazaciclib's potent antitumor activity against mantle cell lymphoma cell lines, independent of their sensitivity to the FDA-approved Bruton's tyrosine kinase inhibitor ibrutinib. Narazaciclib's activity against MCL cell lines was shown to be superior to that of the FDA-approved CDK 4/6 inhibitors palbociclib and ribociclib, and similar to that of the FDA-approved CDK 4/6 inhibitor abemaciclib. Combining narazaciclib with ibrutinib led to synergistic increases in antitumor activity against both ibrutinib-sensitive and ibrutinib-resistant MCL cell lines.

09:12 EDT Ambrx Biopharma presents new preclinical data on ARX517, ARX305 - Ambrx Biopharma, or Ambrx, announced new preclinical data at the 2023 American Association for Cancer Research, AACR, Annual Meeting in Orlando, Florida, held from April 14 to 19, 2023. Poster Title: ARX517, a Next-Generation anti-PSMA Antibody Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer, Demonstrates Anti-Tumor Activity in Enzalutamide-Resistant and Enzalutamide-Sensitive Models and a Clear Therapeutic Index in a Non-Human Primate Model. Highlights: The stability of ARX517 was demonstrated in a non-human primate study; Pharmacokinetic measurements confirm the high stability of ARX517 in circulation with an extended half-life of 11 or 15 days; The main metabolite of ARX517 cytotoxic linker payload, pAF-AS269, was barely measurable in the serum in repeat dosing study; At the highest non-severely toxic dose, ARX517 serum exposure was greater than ARX517 exposure at a pharmacologically active dose in mice, showing a clear therapeutic index; In enzalutamide-sensitive mouse model of prostate cancer, ARX517 clearly demonstrated anti-tumor activity, further the combination of 3 mg/kg ARX517 plus 10 mg/kg enzalutamide delivered an 86% reduction in tumor size; In an enzalutamide-resistant prostate cancer model, three weekly doses of 3 mg/kg of ARX517 significantly inhibited tumor growth by 79% in a dose-dependent manner; In summary, ARX517 exhibits anti-tumor activity in preclinical enzalutamide-resistant and enzalutamide-sensitive prostate cancer models, with high stability in circulation and demonstrates a clear therapeutic index in a non-human primate model. Poster title: ARX517, an anti-PSMA ADC targeting mCRPC resistant or refractory to standard therapies: A phase 1 dose escalation and dose expansion study. Highlights: Ambrx is currently investigating ARX517 in the APEX-01 first-in-human Phase 1, multicenter, dose escalation and dose expansion clinical study to evaluate the safety, pharmacokinetics, and preliminary anti-tumor activity of ARX517 in adult subjects and is currently enrolling patients with advanced prostate cancer whose tumors have progressed following at least two FDA approved treatments for prostate cancer and have met one of the following three criteria: PSA progression defined by a minimum of 2 rising PSA values or radiographic progression by RECIST v 1.1 or disease progression by the presence of new bone lesions. The latest dosing cohort was recently initiated at 2.9 mg/kg. APEX-01 is the only ongoing clinical trial in the United States targeting PSMA with an ADC. Poster Title: Preclinical characterization of ARX305, a next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers. Key Highlights: In a renal cell carcinoma xenograph model, ARX305 dose-dependently inhibited tumor growth and outperformed sunitinib; In another RCC xenograph model, weekly administration of ARX305 resulted in significant, dose-dependent, anti-tumor activity; Pharmacokinetic studies of ARX305 in mice confirms the high ADC stability in circulation with a long terminal half-life of 16.5 days; GLP toxicity study in monkey predicted a clear therapeutic index in human; In summary, ARX305 preclinical data demonstrated ADC stability, strong anti-tumor activity in two RCC models, increased survival of animals in a multiple myeloma disseminated model, and tolerance in non-human primates indicating a wide therapeutic index.

09:11 EDT Abbott says prior headwinds starting to ease - Says seeing increase in diagnostic testing volumes, interest in overall health. Says off to "very good start" to the year. Says core growth platforms have "strong momentum." Comments taken from Q1 earnings conference call.

09:09 EDT ZyVersa announces article published on Inflammasome ASC Inhibitor IC 100 - ZyVersa Therapeutics announces that inflammasome researchers and inventors of ZyVersa's Inflammasome ASC Inhibitor IC 100 from the University of Miami Miller School of Medicine have published a scientific paper in the peer-reviewed journal, Biomaterials. In the paper titled, "Activation of inflammasomes and their effects on neuroinflammation at the microelectrode-tissue interface in intracortical implants," the researchers reported: Glial cell activation was demonstrated at the site of ME implant; Multiple types of inflammasome sensor molecules were upregulated following ME implant injury; NLRP1 and NLRP3, which were upregulated by 48 hours and remained distinctly elevated at 4 weeks, play a vital role in activation of inflammasome complexes during acute and sub-chronic periods following ME-induced injury; In addition to sensor molecules, ASC and Caspase-1 were persistently elevated throughout the implant duration; IL-1beta and IL-18 expression was upregulated soon after ME implantation and remained elevated; Sustained presence of gasdermin D provides evidence of elevated pyroptosis occurring at the injury site, which coincided with a decrease in neuronal density.

09:07 EDT Castor Maritime announces completion of the sale of the M/V Magic Rainbow - Castor Maritime announces that on April 18, 2023, the Company completed the previously announced sale at a price of $12.6 million of the M/V Magic Rainbow, a 2007-built Panamax, by delivering the vessel to its new owners. The Company expects to record during the second quarter of 2023 a net gain on the sale of the M/V Magic Rainbow of approximately $4.4 million, excluding any transaction related costs.

09:04 EDT Beyond Air presents preclinical data for UNO therapy - Beyond Cancer announced promising new in vivo and in vitro data that support the potential of the company's novel Ultra-High Concentration Nitric Oxide, UNO, therapy to treat various types of solid tumors as a single agent and in combination with checkpoint inhibitors. These data were presented today at the American Association for Cancer Research, AACR, Annual Meeting 2023, which is being held in Orlando, Florida from April 14th to 19th via poster presentations for abstract numbers 6327 and 6363. "Today's impressive new data demonstrating that UNO is effective in treating the aggressive murine breast cancer model along with evidence of mPD-L1 upregulation is suggestive of UNO's ability to sensitize tumors to checkpoint therapy. In addition, we are pleased that these new data show efficacious responses from single and repeat doses of UNO," stated Dr. Selena Chaisson, Chief Executive Officer and Director. "These data are exciting additions to the growing body of evidence supporting UNO as a potential therapeutic option for cancer patients. We look forward to the readout of our first-in-human Phase 1 study later this year. Additional trial sites are being activated throughout Israel to expedite enrollment, increase the diversity of patients, and expand awareness of the safe and effective administration of our UNO technology." Abstract #: 6327 describes experiments assessing the ability of single or repeat dosing of UNO to treat 4T1 tumors, which resemble human triple-negative breast cancers. Data showed a statistically significant survival benefit for repeat dosing of UNO compared to anti-CTLA-4 as a monotherapy and in combination with anti-PD-1 compared to anti-PD-1 alone. Results from abstract #: 6363 show that short exposures between 10 seconds to one minute of tumor cells to UNO at increasing concentrations of 25,000 ppm to 100,000 ppm NO significantly upregulate mPD-L1 expression in a dose and time-dependent manner. In addition, in vivo experiments exhibited a statistically significant day 1 increase in M1 macrophages, decrease in Tregs, and reduction in tumor cell viability that was maintained through day 5.

09:03 EDT Longeveron announces first patient dosed in Phase 2 trial of lomecel-B - Longeveron announced that the first patient has been treated with Lomecel-B in its Phase 2 clinical trial in patients with Aging-Related Frailty in Japan. The trial aims to enroll 45 patients and its primary objective is to evaluate safety. "We are excited to announce the dosing of the first patient in our Japanese Aging-Related Frailty trial," said Wa'el Hashad, Longeveron's Chief Executive Officer. "In 2022, Longeveron aligned with the Japan Pharmaceuticals and Medical Devices Agency, on the Phase 2 trial design and we hope the data from this trial will provide support for a limited approval under Japan's Act on the Safety of Regenerative Medicine, which allows regenerative medicine products to be administered to patients by approved hospitals or clinics under the practice of medicine. This is the first use of our U.S.-manufactured product in Japan, and we look forward to advancing Lomecel-B(TM) as a treatment for Aging-Related Frailty in Japan."

09:02 EDT Verisk Analytics solutions selected by Peace Hills General Insurance Company - Peace Hills General Insurance Company is enhancing its claims workflow with the Xactimate and XactAnalysis solutions from Verisk. Peace Hills is using Xactimate to capture information about property damage and help them review estimates with speed and precision. The insurer is using XactAnalysis to send and receive assignments, track claims status, and support the oversight of its contractor network. Both applications can help Peace Hills enhance its workflow and reduce the time it takes to resolve claims.

08:58 EDT BCU, BCU Wealth Advisors partner with CUNA Mutual Group - CUNA Mutual Group announced an agreement to provide BCU and BCU Wealth Advisors a combination of CUNA Mutual Group and the investment and wealth management services of LPL Financial. The relationship between CUNA Mutual Group, LPL, BCU and BCU Wealth Advisors allows BCU and BCU Wealth Advisors to offer more members access to personalized wealth management guidance and continue to position BCU as an innovative leader in the credit union industry.

08:48 EDT Actinium reports data on anti-tumor effects of HER3-targeted radiotherapy - Actinium Pharmaceuticals announces encouraging preclinical proof of concept data at a poster presentation at the American Association for Cancer Research, or AACR, annual Meeting being held April 14-19 in Orlando, Florida. The poster showcased the robust anti-tumor effects of HER3-targeted radiotherapy using multiple therapeutic radionuclides in preclinical models of high unmet need malignancies. Highlights from the AACR poster titled, "Novel HER3 targeting antibody radioconjugates, 225Ac-HER3 ARC and 177Lu-HER3 ARC, exhibit potent antitumor efficacy in HER3-positive solid tumors" include: Actinium's HER3-targeted radiotherapy displayed strong anticancer activity when conjugated to either alpha-emitting Actinium-225 or beta-emitting Lutetium-177 in models of two high unmet need cancers, highlighting its therapeutic potential for HER3+ malignancies; HER3-ARC showed strong target engagement and efficient cellular internalization with compelling cytotoxic activity against established in vitro cellular models; A single dose of HER3-ARC, conjugated to either Actinium-225 or Lutetium-177 showed highly significant reductions in tumor burden in a preclinical ovarian cancer model compared to bevacizumab, an anti-VEGF monoclonal antibody indicated in ovarian cancer; Promising antitumor activity displayed in a preclinical model of colorectal cancer, a highly aggressive malignancy, including a significant reduction in tumor volume when dosed with 225Ac-HER3-ARC; and the consistent overexpression of HER3 in multiple solid tumor types including ovarian, renal, prostate, urothelial, breast, and lung cancers suggests broad utility of a HER3-targeted agent across oncology indications.

08:44 EDT Esperion enters co-promotion agreement with Currax - Esperion announced an agreement with Currax Pharmaceuticals that provides for all of Currax's 72 sales representatives to co-promote NEXLETOL Tablets and NEXLIZET Tablets. This deal more than doubles the sales representatives for NEXLETOL and NEXLIZET and further demonstrates Esperion's focus on driving persistent growth to the business.

08:41 EDT 3D Systems announces Salzburg University surgery using PEEK cranial implant - 3D Systems announced that the University Hospital of Salzburg has successfully applied the company's portfolio of point-of-care additive manufacturing technologies to design and produce its first 3D-printed PEEK cranial implant as a custom device for an individual patient need. These technologies were brought together by the hospital's in-house clinicians to successfully address the patient's needs, providing a customized solution that best positioned the team for success. The hospital used Oqton's D2P software to create 3D models from the patient's CT images and Oqton's Geomagic Freeform to complete the design of the patient-specific occipital prosthesis. The cranial implant was printed using VESTAKEEP(R) i4 3DF PEEK by Evonik on 3D Systems' Kumovis R1 extrusion platform. In commenting on this groundbreaking surgery, Dr. Jeffrey Graves, president and CEO of 3D Systems commented, "We are thrilled for Mr. Trummer and the relief this procedure has given him, and deeply indebted to the talented surgeons and staff at Salzburg University Hospital who brought together for the first time our unique software, hardware, and materials technologies in a point-of-care hospital setting to address his specific needs. We believe that this success provides a real-life demonstration of the potential for enhancing orthopedic outcomes through the use of comprehensive digital manufacturing technologies in a hospital setting."

08:39 EDT SentinelOne appoints Sally Jenkins Chief Marketing Officer. - SentinelOne announced the appointment of Sally Jenkins as Chief Marketing Officer. In this role, Jenkins will be responsible for the planning, development and global execution of the company's marketing strategy to elevate the SentinelOne brand and support industry-leading growth at scale. Jenkins will report directly to SentinelOne CEO Tomer Weingarten. "Sally Jenkins has helped define some of the most influential brands across multiple industries," said Weingarten. "We have aggressive goals to expand our brand presence and market share and Sally's experience in SaaS, data and cybersecurity are the perfect trifecta to achieve them. T A tenured and experienced leader, Jenkins has a proven track record of building brand and demand at leading B2B and B2C companies, including Elastic, Informatica, VMware and Symantec. Jenkins joins SentinelOne from Elastic, a data security and observability solutions provider built on Elasticsearch, where she successfully transformed the company's positioning, marketing strategy and vision to meet the hypergrowth company's evolving needs, contributing to a 300% revenue increase during her tenure. Prior to Elastic, she was CMO at Informatica, an AI-powered data management company, where she was instrumental in repositioning the company as a leader in the enterprise cloud data management category.

08:38 EDT Vita Coco announces 'The Coconut Grove' experience on Roblox - The company said, "Starting today, The Vita Coco Company is giving consumers the opportunity to immerse themselves in the world of coconut farming and harvest coconuts in "The Coconut Grove" on Roblox. In the brand's very first 3D simulation experience, Vita Coco will match all coconut seedlings planted by Roblox users in the experience - up to 100,000 - and distribute real seedlings through the company's new Seedlings for Sustainability initiative. In honor of Earth Day, Vita Coco will distribute five seedlings for every one seedling planted in The Coconut Grove Experience on April 22. To join the experience, simply search for "The Coconut Grove" on your Roblox app."

08:38 EDT Mawson Infrastructure sells Texas sites for $8.5M - Mawson Infrastructure announced that it has signed and closed a binding sale agreement for Mawson's greenfield sites in Midland, Texas, effective April 18. The sale price was $8.5M in cash and stablecoins. The transaction involved the sale of 100% of Mawson's subsidiary Luna Squares Texas, which held the relevant lease agreements and related contracts. In addition, Mawson sold 59 transformers which were earmarked for these Texas sites. The buyer is a fund managed by Mainnet Capital, a Singapore-based fund manager, called M Turing VCC Oracle Phase 1 Fund. The sale of the Texas sites allows Mawson to focus all attention on its current 240 MW of facilities in Pennsylvania. The proceeds of the sale will be used for further debt reduction, as well as funding future expansions across Mawson's other sites, including the acquisition of additional ASIC miners. Mawson is scheduled to turn on an added 70 MW at its Midland, PA site, and an initial 12 MW at its Sharon, Pennsylvania site in Q2. Mawson expects to have 132 MW online during Q2, representing enough power for up to 38,808 ASIC miners, operating at approximately 4.2 EH/second. This capacity expansion could potentially generate up to approximately 11.025 BTC per day, or approximately $120M in revenue per year, which would be split between Mawson and its hosting customers.

08:37 EDT Imunon presents poster at AACR annual meeting on IMNN-001 - IMUNON announces that a poster highlighting the Company's DNA-based immunotherapy IMNN-001 was presented on April 18 at the American Association for Cancer Research, AACR, Annual Meeting in Orlando. IMNN-001 is a DNA-based interleukin-12 immunotherapy currently in Phase 2 clinical development for the localized treatment of advanced ovarian cancer. The poster is titled "Efficacy of IMNN-001, an Interleukin-12 Immune Gene Therapy, at Different Dose Frequencies." In the study, IMNN-001 dosing regimens were examined for efficacy in ID8 tumor-bearing mice either weekly, every two weeks or every three weeks. Six animals from each group dosed were harvested for translational research after five weekly (three every two-week and two every three-week) treatments, respectively. The remaining four animals in each group were followed for weight change and survival. Additionally, TR evaluated change in ascites T cell populations. There was a gradual rise in tumor burden and mortality in all treatment groups with comparable rates between the once weekly and once every two weeks regimen. Researchers concluded that IMNN-001 demonstrated stimulation of the immune response in the ID8 ovarian tumor model. Of the three dosing regimens tested, the once every 2-week regimen demonstrated comparability to the weekly regimen while showing superiority to the once every 3-week regimen, particularly with respect to mortality and tumor burden. Thus, exploring once every 2-week dosing of IMNN-001 in human studies is warranted.

08:36 EDT Morgan Stanley expects markets to remain 'choppy' for next several months - 2023 is likely to end on a "constructive" note in most areas, CEO James Gorman said.

08:36 EDT ClearSign receives purchase order for two process heaters in California refinery - ClearSign Technologies announces the receipt of a purchase order to complete the detailed engineering of burners for two process heaters in a California refinery. This refinery was an early customer and has ongoing experience with the operation and performance of the ClearSign burner technology. This purchase order states that the procurement and fabrication of burners may be added at a later date, or not at all. If this order does continue to the supply of our equipment, it would displace an existing SCR system and help the refinery adhere to the stricter emissions regulations in California.

08:35 EDT TD Holdings subsidiary achieves record breaking results in Q1 - TD Holdings announced that its controlling subsidiary Shenzhen Tongdow Internet Technology, a leading integrated service provider for an online to offline e-commerce commodities trading platform Tongdow.com, achieved record-breaking operation results in the Q1 with a gross merchandise value of RMB99B, increased by RMB11B from the same period of last year with a 12.5% year-over-year growth. Previously, Frost & Sullivan released an industry report entitled "China's B2B E-commerce Platform for Non-ferrous Metals Market, Independent Market Research", which indicates that in 2021, the top three B2B e-commerce platforms for non-ferrous metals in terms of GMV are Tongdow ranked No.1 at RMB440B, Smm.cn ranked No.2 at RMB100B, and Mymetal.net ranked No.3 at RMB90B.

08:34 EDT Ryvyl announces strategic partnership with Intercash - RYVYL announced it has entered into a strategic partnership with Intercash to collaborate on card issuance for customers in the European Economic Area, EEA. Through the collaboration, business customers can now offer co-branded debit and prepaid cards to untapped consumer markets leveraging RYVYL's new Banking-as-a-Service platform as the infrastructure. "Until now, certain B2B customers, through no fault of their own, have been largely excluded from using this important brand-building marketing tool," says Fredi Nisan, Co-Founder and CEO of RYVYL. "By leveraging our partnership with Intercash, we are excited to be able to bring businesses in Europe the ability to create their own customized cards." The agreement is another example of RYVYL's recent successes signing international financial institutions such as Paydek, Xace and others to its BaaS solution. The company expects to process more than $100 million in BaaS transaction volume per month when fully ramped up.

08:34 EDT Sunergy enters business combination agreement with ESGEN Acquisition - Sunergy Renewables and ESGEN Acquisition Corp. announced a definitive agreement for a business combination that would result in the combined company becoming a publicly listed company on the Nasdaq Stock Exchange. Founded in 2005 and headquartered in New Port Richey, Florida, Sunergy provides photovoltaic solar and battery-based power as well as storage systems for residential consumers. The Company's carefully assembled product portfolio of solar products, energy-efficient appliances, energy storage, insulation, and roofing services provides a range of benefits to homeowners, including meaningful utility cost savings, superior reliability compared to alternative sources, and energy independence. Sunergy has a strong track record of financial performance and profitability. In 2022, the Company delivered approximately $123 million in revenue and approximately $11 million in EBITDA, underpinned by nearly 2,400 installations performed during the year. Sunergy sells residential solar systems through a proprietary and differentiated sales approach that seeks to maximize lead generation and conversion efficiencies. The Company leverages a custom software platform to augment sales efforts and uses a customer relationship management system to actively track key performance indicators across the sales cycle. Sunergy believes its multi-tiered sales strategy minimizes customer acquisition costs and maximizes sales representative output. Additionally, Sunergy's integrated installation business allows for greater control of the customer relationship. Benefits of this strategy include greater profitability potential, efficient navigation of local regulatory processes, and sustained customer satisfaction, which can lead to increased speed of project completion. Sunergy's methodical geographic expansion is focused on targeting specific geographic areas having attractive solar and distributed energy characteristics with less saturation from competing solutions, including high-growth markets in Florida, Texas, and Arkansas. The Transaction is currently anticipated to generate gross proceeds of up to approximately $65 million of cash, underpinned by a $10 million participation in the common stock PIPE by ESGEN's sponsor, ESGEN at $10.00 per share. Proceeds will be used to fund operations and growth. The pro forma implied enterprise value of the combined company is expected to be $475 million. After the Transaction, the Board of Directors of the combined company will include representatives from both Sunergy and ESGEN. The Board of Directors of ESGEN and the board of managers of Sunergy have unanimously approved the Transaction. Completion of the proposed Transaction is subject to customary closing conditions and is anticipated to occur in the fourth quarter of 2023.

08:33 EDT Veru enter into supply agreement with Afaxys to access FC2 female condom - Veru announced it has entered into a Purchasing Agreement with Afaxys Group Services to offer Veru's FC2 Female Condom through the AGS Group Purchasing Organization for the benefit of up to 31 million women and men that depend on community and public health centers for essential healthcare. Afaxys is a trusted, mission-driven healthcare company that uniquely partners with those who serve community and public health patients to ensure access to affordable sexual and reproductive healthcare. Under the terms of the agreement, Afaxys members will have access to a preferred pricing model for Veru's FC2 Female Condom, an FDA-approved method of contraception indicated for preventing pregnancy and the transmission of sexually transmitted infections, including HIV/AIDS. As a result, Afaxys' healthcare provider membership is guaranteed reliable and affordable access to the FC2 Female Condom for their patients. "We applaud Afaxys for growing its portfolio of contraceptive product offerings with the addition of a non-hormonal contraceptive method, the FC2 Female Condom," said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru. "This partnership will bring affordability and accessibility to family planning clinics, community health centers, and qualified private practices serving underrepresented women, an important and large U.S. public sector channel."

08:31 EDT Synchrony says delinquencies to approach pre-pandemic levels by mid-year - Sees FY23 loan receivables growth 8%-10%. Says net interest income growth driven primarily by growth in average loan receivables. Says increase in other expenses primarily driven by higher employee costs, operational losses and technology investments. Says Q1 purchase volume growth and payment rate moderation exceeded expectations. Comments and guidance taken from Q1 earnings conference call.

08:19 EDT Panbela Therapeutics to present on SBP-101 results at AACR meeting - Panbela Therapeutics announces a poster presentation highlighting the results for ivospemin as a polyamine metabolism modulator in ovarian cancer at the American Association for Cancer Research, taking place April 14-19, 2023. The work reflects the Company's ongoing collaboration with Johns Hopkins University School of Medicine. The poster highlights the efficacy of SBP-101 in combination with standard of care chemotherapy agents used to treat platinum-resistant ovarian cancer. Treatment with gemcitabine, topotecan, and doxorubicin have been shown to significantly increase the in vitro toxicity of SBP-101 in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines. Paclitaxel and docetaxel have been shown to not have any added benefit in vitro to SBP-101 alone. Utilizing the VDID8+ murine ovarian cancer model, the efficacy of SBP-101 in combination with either gemcitabine, topotecan, or doxorubicin was evaluated. Gemcitabine and topotecan alone had little effect on the overall survival of the mice, whereas either SBP-101 or doxorubicin treatment alone significantly increased median mouse survival time. The addition of SBP-101 improved the survival of mice treated with any of the three chemotherapeutics. The SBP-101 and doxorubicin combination mice had the greatest survival time with a 265% increase in median survival compared to untreated animals. Additionally, combining DFMO with ivospemin in vitro resulted in a cooperative antiproliferative response. DFMO has been shown to be well tolerated and can influence immune cells to promote a more immune-friendly tumor microenvironment. Future experiments will evaluate the effect of adding DFMO to ivospemin treatment as well as the influence on immune cells within the tumor microenvironment. The poster concludes that the treatment of C57Bl/6 mice containing VDID8+ ovarian cancer with SBP-101 in combination with doxorubicin significantly prolonged survival and decreased overall tumor burden. Future studies will be designed to evaluate the effects of SBP-101 in combination with other polyamine metabolism modulators as well as with immune modulators.

08:17 EDT Camber Energy, Viking Energy enter amendment to merger agreement - Camber Energy and Viking Energy Group announce that on April 18, 2023, they entered into an amendment to the Amended and Restated Agreement and Plan of Merger, dated as of February 15, 2021, regarding the full combination of the two entities. The Merger Agreement provides that, upon the terms and subject to the conditions set forth therein, Viking Merger Sub, Inc., a wholly owned subsidiary of Camber, will merge with and into Viking, with Viking surviving the Merger as a wholly owned subsidiary of Camber and Camber remaining the sole publicly-traded entity. If the Merger is consummated, Viking's shareholders would receive one share of Camber's common stock in exchange for each of their shares of Viking's common stock , and would benefit from owning shares of a company listed on a national stock exchange platform with greater liquidity and an established trading history. If the Merger is completed, Camber would acquire full legal and accounting control of Viking, permitting Camber to, among other things, report underlying subsidiary revenues at the Camber level, and Camber would benefit directly and fully from Viking's business activities, including as it relates to Viking's interests in the following: Custom Energy & Power Solutions Business; Exclusive License to a Patented Clean Energy & Carbon-Capture system; Intellectual property rights to a fully developed, patented ready-for-market proprietary Medical & Bio-Hazard Waste Treatment system using Ozone Technology; and Patent pending ready-for-market proprietary Open Conductor Detection systems. As a next step concerning the Merger, Camber intends to file a preliminary registration statement on Form S-4 with the Securities and Exchange Commission.

08:13 EDT Agrify enters warrant inducement letters to raise up to $1.84M in proceeds - Agrify has entered into warrant inducement letters to raise up to $1.84 million in gross proceeds from the exercise of 10,651,430 common stock warrants issued in the Company's public offering from December, 2022, or the Existing Warrants. On April 18, 2023, the Company reduced the exercise price of all the Existing Warrants from $0.65 per share to $0.1725 per share. On such date, Agrify also entered into warrant inducement offer letters with certain investors pursuant to which the investors' may exercise 10,651,430 Existing Warrants at the reduced exercise price of $0.1725, and the Company will issue to such investors new warrants to purchase 200% of the shares exercised pursuant to the Existing Warrants from April 18, 2023 to 9:00am on April 21, 2023. Such new warrants will become exercisable six months after issuance, have an exercise price of $0.1725 and a five year term from their initial exercise date, which will, among other things, be reduced to the extent the Company issues securities for a lower purchase price, subject to certain exceptions and substantially consistent with the equivalent term in the Existing Warrants. Additionally, if the exercise of the Existing Warrants by the warrantholder would cause the warrantholder to exceed the beneficial ownership limitation in the warrant agreement for the Existing Warrants, the Company will, among other things, only issue such number of Existing Warrants to the warrantholder that would not cause the warrantholder to exceed the maximum number of shares of common stock permitted, with the balance to be held in abeyance until such shares can be delivered to the holder within such beneficial ownership limitations. If all are exercised, the exercise of the 10,651,430 Existing Warrants is expected to result in gross proceeds to the Company of $1.84 million.

08:11 EDT SeaStar announces activation of first clinical stie in NEUTRALIZE-AKI trial - SeaStar Medical announces the activation of Good Samaritan Regional Medical Center in Corvallis, Oregon, as the first clinical site in its pivotal NEUTRALIZE-AKI trial. This trial, expected to include up to 30 U.S. sites, is evaluating the safety and efficacy of SeaStar Medical's patented, first-in-class, cell-directed Selective Cytopheretic Device extracorporeal therapy in critically ill adults with acute kidney injury requiring continuous kidney replacement therapy. "We recently received FDA approval to begin this pivotal trial and activated the first clinical site in record time, with many more sites expected to come onboard in the near term," said Kevin Chung, MD, Chief Medical Officer of SeaStar Medical. "Previous clinical studies with the SCD have demonstrated reduced mortality and dialysis dependency in these critically ill patients, and we look forward to rapid enrollment of eligible patients into the NEUTRALIZE-AKI trial to validate these results." Four non-COVID completed studies evaluating the safety and feasibility of the SCD in adults and pediatric patients with AKI requiring CKRT showed Day 60 reductions in mortality of up to 50% and no dialysis dependency, compared with 15% to 25% dialysis dependency in historical controls.

08:10 EDT Indaptus Therapeutics presents data on preclinical efficacy of Decoy - Indaptus Therapeutics announces data presented in a poster at the American Association for Cancer Research, AACR, annual scientific conference on the Company's Decoy anti-tumor platform. The poster, titled, "A systemically administered killed bacteria-based multiple immune receptor agonist for pulsed anti-tumor immunotherapy," authored by Michael Newman, Ph.D., the Company's Founder and Chief Scientific Officer, was presented Tuesday, April 18, 2023. Highlights included: Decoy10 is a novel, attenuated and stabilized multi-TLR, NLR and STING agonist bacteria-based immunotherapy that demonstrated 90% reduction of LPS-endotoxin activity and use of 100% killed, non-pathogenic bacteria; Decoy10 inhibited tumor growth, metastasis, and induced tumor regressions as a single agent. Regressions were also seen with Decoy10 in combination with a non-steroidal anti-inflammatory drug , an anti-PD-1 checkpoint inhibitor, low-dose chemotherapy, and LDC plus a targeted antibody. The data demonstrated that Decoy10 contains agonists of TLR2, TLR4, TLR8, TLR9, NOD2 and STING, conferring the ability to activate both innate and adaptive immune pathways in tumors after a single safe i.v. dose of Decoy10 in combination with anti-PD-1 checkpoint therapy, an NSAID or both. In vivo anti-tumor activity was seen with colorectal, breast, hepatocellular, pancreatic carcinomas, and non-Hodgkin's lymphomas in pre-clinical models.

08:08 EDT Enlivex Therapeutics receives notice of allowance for US patent on Allocetra - Enlivex Therapeutics announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for patent application number 16/076,026. Once issued, the resulting patent will provide Enlivex with added intellectual property protection through at least 2036 with claims covering methods of using Allocetra in combination with chimeric antigen receptor, CAR, T-cell therapy to treat, ameliorate or allveiate tumors. The Company expects that this new patent will be issued in the United States during 2023.

08:06 EDT Chembio Diagnostics urges stockholders to tender shares - The company said, "We strongly urge you to tender your shares of common stock of Chembio Diagnostics in the tender offer being made by Biosynex and its affiliates. The tender offer is the first step in a proposed merger between Chembio and Biosynex. Biosynex has agreed to pay $0.45 per share in cash to each of our stockholders who tender their shares prior to the expiration of the tender offer. The tender offer expires at 6:00 p.m. New York City time on April 26, 2023. Biosynex previously announced extensions of the tender offer until 6:00 p.m., New York City time, on March 28, 2023, and until 6:00 p.m., New York City time, on April 12, 2023. As of 6:00 p.m., New York City time, on April 12, 2023, approximately 17,738,529 shares had been validly tendered and not validly withdrawn from the tender offer, representing approximately 48.3% of the shares then outstanding. On April 13, 2023, Biosynex announced a third extension of the tender offer until 6:00 p.m., New York City time, on April 26, 2023. If less than a majority of the outstanding shares of Chembio common stock are tendered, the tender offer will not be completed and Chembio will not merge with Biosynex. Biosynex is not required to further extend the tender offer and may terminate the tender offer and the merger agreement if more than 50% of the outstanding shares are not validly tendered by 6:00 p.m., New York City time, on April 26, 2023. Chembio management and the Board of Directors strongly support the tender offer and merger with Biosynex. We believe it is in the best interest of our stockholders and recommend that you tender your shares as soon as possible. We urge you to tender your shares today!"

08:05 EDT Genetic announces publication on geneType prostate cancer risk test - Genetic Technologies announces the publication of a research paper in "The Prostate" validating the utilisation of geneType Prostate Cancer Risk Assessment Test in the identification of men who are at increased risk of this serious disease.Highlights: geneType Prostate Cancer Risk Assessment Test was able to identify 23% more men at high risk of developing prostate cancer than family history alone. The study demonstrated that geneType could enable a more targeted approach to Prostate Specific Antigen screening of high-risk men - ultimately providing far greater utility of the PSA screening test. The study utilised a prospective cohort of almost 200,000 men from the UK Biobank. The publication highlights GTG's commitment to ongoing scientific development of the geneType suite of risk assessment tests - being the 5th publication in the last 6 months - covering ovarian cancer, cardiovascular disease & type 2 diabetes, breast cancer and prostate cancer. The paper entitled: Development and validation of a simple prostate cancer risk prediction model based on age, family history, and polygenic risk was published in the journal "The Prostate" by GTG's scientific team including Dr Erika Spaeth, Dr Richard Allman, Dr Gillian Dite and Dr Nicholas Murphy. The study demonstrated that geneType Prostate Cancer Risk Assessment Test offered a significant improvement in risk assessment when compared with age and family history in assessing a man's risk of developing prostate cancer. According to the study, family history alone had a 23% underestimation of risk. Importantly, geneType was we also able to identify men at very low risk of developing prostate cancer.

08:04 EDT Atlas Technical Consultants acquired by GI Partners - Atlas Technical Consultantsy announced the completion of its acquisition by GI Partners, in an all-cash transaction valued at approximately $1.05B, including outstanding debt. The agreement to be acquired was previously announced on January 31, 2023 and approved by Atlas stockholders at Atlas' Special Meeting of Stockholders held on March 29, 2023. With the completion of the transaction, Atlas stockholders will receive $12.25 per share in cash for each share of Atlas common stock they owned, which represents a premium of approximately 124 percent over Atlas' unaffected closing share price of $5.47 on January 30, 2023. Atlas' common stock has ceased trading and will be delisted from Nasdaq.

08:03 EDT VYNE Therapeutics announces preclinical data for inhaled formulation of VYN201 - VYNE Therapeutics announced new preclinical data showing the positive effect of its novel pan-BET inhibitor, VYN201, in a preclinical model of idiopathic pulmonary fibrosis. "The data from this well-validated preclinical model of IPF clearly demonstrates VYN201's potential to deliver a potent anti-inflammatory and anti-fibrotic response," said David Domzalski, President and Chief Executive Officer of VYNE. "These data in IPF support our thesis that VYN201 has potential utility as a locally-administered therapy across a variety of immuno-inflammatory indications and further underscores the potential value of our InhiBETTM BET inhibitor platform." Key findings: Ashcroft Scoring and Hydroxyproline Levels: VYN201 at 0.5 mg/ml and 1 mg/ml demonstrated statistically significant reductions in Ashcroft scores and levels of the tissue fibrosis biomarker, hydroxyproline, compared to the placebo control group at day 21. Mean control-adjusted lung fibrosis scores for VYN201 1 mg/ml were 65.8% lower compared to the placebo control group at day 21. Blood Oxygen Saturation: VYN201 demonstrated a dose-dependent improvement in blood oxygen saturation. Mean blood oxygen saturation for the VYN201 1 mg/ml group was 92.4% at day 21, an 8.8% improvement compared to the placebo group. Mean blood oxygen saturation for the untreated and unstimulated control group was 95.2%. Volumetric Lung Function: Thoracic tomography revealed that VYN201 treatment groups demonstrated a dose-dependent improvement in functional lung volume compared to the placebo control group. These data correlate with an increase in blood oxygen saturation and reduction in Ashcroft fibrosis scores. Treatment with VYN201 1 mg/ml resulted in a 51.8% mean improvement in functional lung volume compared to animals receiving placebo treatment.

08:02 EDT Keros Therapeutics appoints Alpna Seth to board of directors - Keros Therapeutics announced that it appointed Alpna Seth, Ph.D., to its Board of Directors, effective May 1, 2023. Dr. Seth served as the President and Chief Executive Officer of Nura Bio Inc. for three years, until she retired in October 2022.

08:01 EDT Raytheon Technologies awarded $237M counter-UAS contract - Raytheon Technologies was awarded a $237M U.S. Army contract for Ku-band Radio Frequency Sensors and Coyote effectors to detect and defeat unmanned aircraft. The contract includes a combination of fixed-site and mobile systems as well as a quantity of effectors, designated to support the Army's U.S Central Command operations.

07:48 EDT Wildpack Beverage closes bridge loan, terminates convertible term loan - Wildpack Beverage announces the closing of a term loan in the aggregate principal amount of $12,500,000 from Sandton Credit Solutions Master Fund V, an affiliate of Sandton Capital Partners, pursuant to a loan agreement between Sandton and the Company's indirect wholly-owned subsidiaries, as borrowers. The Bridge Loan is comprised of a 12-month secured term loan in the principal amount of $12,500,000, bearing interest at a rate of 13.00% per annum. All interest accrued during the term of the Bridge Loan will be added to the principal balance and will thereafter accrue interest, for clarity no cash will be paid during the term. Proceeds from the Bridge Loan will be utilized for facility improvements and working capital to support and continue Wildpack's growth trajectory in sales and production. The Bridge Loan is secured by a first priority lien on all assets of the Company and its subsidiaries and is guaranteed by the Company and its subsidiaries. Wildpack and Sandton have also executed a term sheet outlining a $25,000,000 interest-bearing four-year term loan which would be convertible into 49% of the equity of the Company to replace the Bridge Loan. The Convertible Loan is to be a four-year secured term loan in the principal amount of $25,000,000, bearing interest at a rate of 13.00% per annum accrued but not payable until after the first year. The Convertible Loan is to be secured by a first priority lien on all assets of the Company and its subsidiaries and is to be guaranteed by the Company and its subsidiaries. The Convertible Loan will be subject to the approval of the TSX Venture Exchange. In the event that the Bridge Loan is not replaced by the Convertible Loan within 120 calendar days of the closing date, for any reason other than Lender's election to not to enter into such refinance transaction on the terms set forth in the Term Sheet, or the failure of the TSX Venture Exchange to clear any personal information forms required in connection therewith, then the original principal balance of the Bridge Loan will be increased by $1,250,000, effective as of the Step up Date, and all accrued interest will be recalculated consistent therewith. The Company also announces that the parties will not be proceeding with the previously announced $20,000,000 interest-bearing convertible term loan between the Company's wholly-owned subsidiary, Thirsty Cat and MBV-WP.

07:39 EDT Rekor Systems awarded $14.14M in new multiyear contracts - Rekor Systems has been selected as a preferred vendor for both the South Carolina Department of Transportation and the Florida Department of Transportation. The Company will provide its Class, Count & Speed Application as part of the Rekor Discover platform along with its non-intrusive Rekor Edge Flex traffic data collection systems to gather traffic data throughout both states. SCDOT and FDOT awarded Rekor these contracts after a rigorous evaluation of the proposals submitted. The combined total contract value is $14,145,000, over terms of four and six years, for SCDOT and FDOT, respectively.

07:38 EDT Charge Enterprises reports backlog surpasses $100M, backs growth strategy - Charge Enterprises reported record backlog after the close of the first quarter 2023 and reaffirmed its commitment to pursuing growth within the EV charging infrastructure sector. "We have demonstrated through our record backlog that we continue to provide essential infrastructure services in the EV charging, broadband infrastructure and electrical infrastructure markets. The growth of our backlog is a testament to the leadership of our infrastructure divisions, the processes that we are implementing, and the teams that we are building," said Andrew Fox, CEO of Charge. "The growth of our EV charging infrastructure division, Charge Infrastructure, reinforces our strategy to focus on the EV transition as a pillar of our company's future. CI's backlog growth, now representing over 20% of the total, supports that our unique and specialized offering is valued by our clients. Our 150 years of automotive OEM expertise, investment in educating our customers while we remain focused on white-glove service, and our commitment to deliver client-centric solutions throughout the project differentiates Charge. We continue to focus on our mission to be the trusted advisor for EV charging infrastructure ecosystems, and we are grateful to play a role in the transition from gas to electric powered vehicles," Fox concluded.

07:35 EDT Ally Financial CEO says 'we maintain healthy levels of liquidity' - "Ally's operating results amid this dynamic macro environment highlight the continued strength of our franchises," said CEO Jeffrey Brown. "Despite the heightened volatility in markets, the team remained focused on what we can control and delivered another quarter of compelling operational results. We maintain healthy levels of liquidity, capital and reserves, positioning us well for a variety of outcomes ahead. Additionally, our deposit franchise demonstrated its resilience in large part due to the customer-centric approach we've taken since its inception. At Ally Bank, we generated the highest quarterly customer growth on record with 126 thousand net new customers. In total, retail deposit customers now total 2.8 million, up 12 percent year over year. This growth positions us well going forward, but also highlights the value of the Ally brand in times of market uncertainty. Our Dealer Financial Services business continues to demonstrate the benefits of scale with $9.5 billion in consumer originations with a retail yield approaching 11 percent as we've added more than 400 basis points during this tightening cycle. As we progress throughout 2023, we continue to see opportunities across all our businesses, but are mindful of the current environment and are making necessary adjustments to manage risks. Our focus remains on risk-adjusted returns, which may lead to slightly lower origination levels as we look to tighten underwriting in certain segments that don't meet return thresholds. Our 11,700 teammates are powered by our LEAD core values and remain allies for our 11 million customers. Looking ahead, we are positioned to navigate this dynamic environment, demonstrate the strength of the franchises we've built, and deliver results for all stakeholders."

07:34 EDT Transocean provides quarterly fleet status report - Transocean issued a quarterly Fleet Status Report that provides the current status of, and contract information for, the company's fleet of offshore drilling rigs. This quarter's report includes the following updates: Transocean Enabler - Awarded a 19-well contract in Norway at a current rate of $377,000 per day, as adjusted for foreign currency exchange plus eight option wells. Transocean Encourage - Awarded a nine-well contract in Norway at a rate of $350,000 per day. Transocean Endurance - Awarded a multi-well plug and abandonment contract in Australia at a rate of $380,000 per day plus options. Transocean Norge - Customers exercised four one-well options in Norway at $338,000 per day, $358,000 per day, $358,000 per day, and $408,000 per day, respectively, as adjusted for foreign currency exchange. The aggregate incremental backlog associated with these fixtures is approximately $546 million. As of April 18, 2023, the company's total backlog is approximately $8.6 billion.

07:32 EDT Bombardier achieves regulatory approval for installation of Smart Link Device - Bombardier announced major advancements in its comprehensive Smart Link Plus connected aircraft system with several key regulatory approvals. The company has recently achieved essential TC, EASA and FAA approvals for almost its entire fleet of Challenger and Global aircraft. With these approvals, operators of all in-service Challenger 300, Challenger 350, Challenger 3500, Challenger 605 and Challenger 650, as well as Global 5000, Global 6000, Global Express and Global XRS aircraft will be able to install the innovative Smart Link Plus aircraft health management system on their business jets. The Smart Link Plus connected aircraft system was first introduced on the Bombardier flagship Global 7500 aircraft and customers continue to benefit from its advanced data-driven capabilities. Now, a strong majority of current Global 7500 aircraft customers have enrolled in the Smart Link Plus service, and Bombardier has been gradually expanding the program to offer retrofit options to its in-service fleet of Challenger and Global aircraft. The Smart Link Plus system will also be installed on all new Global 8000 aircraft as a standard feature. Bombardier is working to finalize all regulatory approvals for operators of Challenger 604 and Global 5500 and Global 6500 aircraft. Approvals are expected from late 2023 through early 2024.

07:22 EDT Abbott reports Q1 worldwide COVID-19 testing sales $730M vs. $3.3B last year

07:16 EDT Fairfax Financial to acquire additional 46.32% interest in Gulf Insurance Group - Fairfax Financial Holdings and Kuwait Projects Company entered into an agreement pursuant to which certain affiliates of FFHL will acquire all of the shares of Gulf Insurance Group under the control of KIPCO and certain of its affiliates, representing approximately 46.32% of the equity of GIG. Under the terms of the Agreement, the KIPCO Sellers' shares in GIG will be acquired by Fairfax for aggregate proceeds to KIPCO of 263,653,200 Kuwaiti Dinar, representing a price per share of 2.00 Kuwaiti Dinar per share, subject to a reduction by the amount of any dividends received by the KIPCO Sellers after January 1, 2023. Following the closing of the Transaction, Fairfax's equity interest in GIG will increase from 43.69% to 90.01%. In accordance with applicable Kuwaiti regulatory requirements and the rules of the Boursa Kuwait, the exchange on which GIG's shares are traded, the purchase price payable to the KIPCO Sellers in connection with the Transaction will be paid by Fairfax in full in Kuwaiti Dinar on closing. Pursuant to the terms of the Agreement, immediately following the settlement of the Transaction, the KIPCO Sellers shall return to Fairfax in cash the full purchase price less an amount of Kuwaiti Dinar equal to $200 million, together with a cash payment equal to all dividends received by the KIPCO Sellers from GIG after January 1, 2023, and Fairfax will deliver to KIPCO a payment deed requiring Fairfax to make four equal annual payments of $165 million to KIPCO beginning on the first anniversary of closing of the Transaction. The Transaction is subject to the receipt of all necessary approvals from applicable regulators, including merger control, capital markets, stock exchange and insurance regulators in each relevant jurisdiction in which GIG operates, and the satisfaction of other customary closing conditions, including a condition that the volume-weighted average price of the publicly-traded shares of GIG in the six month period prior to closing must not exceed the price per share to be paid to the KIPCO Sellers. Closing of the Transaction is currently expected to occur in the second half of 2023. In accordance with regulations of the Capital Markets Authority of Kuwait, the closing of the Transaction between KIPCO and Fairfax will require Fairfax to initiate a mandatory tender offer to all other holders of GIG shares. Fairfax expects the launch of the mandatory tender offer to occur shortly after the closing of the Transaction, and in any event within thirty days thereafter.

07:09 EDT B2Gold completes acquisition of Sabina Gold & Silver - B2Gold announced that it has completed the previously announced plan of arrangement to acquire all of the issued and outstanding common shares of Sabina Gold & Silver Corp. The Arrangement results in B2Gold acquiring Sabina's 100% owned Back River Gold District located in Nunavut, Canada. The Back River Gold District consists of five mineral claims blocks along an 80 kilometre belt. The most advanced project in the district, Goose, is fully permitted, construction ready, and has been de-risked with significant infrastructure currently in place. B2Gold's management team has strong northern construction expertise and experience to deliver the fully permitted Goose project and the financial resources to develop the significant gold resource endowment at the Back River Gold District into a large, long life mining complex. Under the terms of the Arrangement, Sabina shareholders received 0.3867 B2Gold common shares per Sabina common share. In aggregate, B2Gold will issue approximately 216 million B2Gold Shares under the Arrangement. The Sabina common shares are expected to be delisted from the TSX and the OTCQX at market close on April 21, 2023. Following the delisting, B2Gold intends to apply for Sabina to cease to be a reporting issuer under applicable Canadian securities laws.

07:08 EDT Agios Pharmaceuticals appoints Capello to board of directors - Agios Pharmaceuticals (AGIO) announced that Jeffrey Capello has been appointed to its board of directors. Agios also announced that Paul Clancy will step down from the board of directors at the end of his term, effective June 13, 2023. Most recently, he was the chief financial officer for Biogen (BIIB), where he partnered with the executive team to achieve consistent and predictable financial outcomes while enhancing the R&D pipeline and implementing a disciplined capital allocation process.

07:07 EDT Renalytix publishes new real-world evidence on KidneyIntelX utility - Renalytix announces the release of new real-world evidence case studies published in the peer reviewed journal Diabetic Nephropathy entitled: "The Need for Risk Stratification in Type 2 Diabetes and Chronic Kidney Disease: Proposed Clinical Value of KidneyIntelX." The publication underscores the importance of enabling early risk assessment in diabetic kidney disease to reduce likelihood of progression to kidney failure and dialysis. This publication highlights the limitations of current tools commonly used in chronic kidney disease, CKD, management and how KidneyIntelX can optimize care with the examination of four patient cases under clinical management by four different physicians. Bioprognostic tools, such as KidneyIntelX, incorporate well-validated prognostic protein biomarkers integrated with key clinical variables from a patient's health record can help predict rapid kidney function decline in these early-stage CKD patients, proactively optimize care, and change the trajectory of chronic kidney disease before severe or irreversible kidney damage occurs.

07:04 EDT Nasdaq increases quarterly dividend 10% to 22c per share - The Board of Directors of Nasdaq has declared a regular quarterly dividend of 22c per share on the company's outstanding common stock, a 10% increase from the previous quarter. The dividend is payable on June 30, 2023, to shareholders of record at the close of business on June 16, 2023. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Directors.

07:04 EDT Surmodics announces first patient use of radial access microcatheter - Surmodics announced that Dr. Ankur Lodha, Lafayette, La., and Dr. Pradeep Nair, Houma, La., are the first physicians to use the company's Sublime adial access microcatheter. Drs. Lodha and Nair are interventional cardiologists at the Cardiovascular Institute of the South. The Sublime microcatheter is in limited market evaluation. The full suite of Sublime microcatheters will be launched in FY 2024. The Sublime portfolio will include the industry's first suite of 0.014", 0.018", and 0.035" high-performance peripheral microcatheters. "For peripheral as well as coronary interventions, radial access is safer than femoral access and much preferred by patients," said Dr. Lodha. "I'm pleased to report that the Sublime microcatheter performed exceptionally well during our first uses of the device in treating peripheral arterial disease." "The lack of long-length, high-performance catheters for peripheral procedures has slowed adoption of radial access for treatment of lower extremity artery disease," added Dr. Nair. "Sublime microcatheters will fill a major gap in the peripheral-intervention toolkit, including for procedures from access sites other than the wrist." The Sublime microcatheter is in limited market evaluation. The full suite of Sublime microcatheters will be launched in FY 2024. The Sublime portfolio will include the industry's first suite of 0.014", 0.018", and 0.035" high-performance peripheral microcatheters. "For peripheral as well as coronary interventions, radial access is safer than femoral access and much preferred by patients," said Dr. Lodha. "I'm pleased to report that the Sublime microcatheter performed exceptionally well during our first uses of the device in treating peripheral arterial disease."

07:02 EDT U.S. Silica announces favorable Final Judgement in lawsuit against AKW - U.S. Silica Holdings announced that it received the Final Judgement in its lawsuit against Amberger Kaolinwerke, or AKW,in the federal court of the Eastern District of Texas. U.S. Silica filed its lawsuit against AKW in September 2020, alleging that AKW was infringing multiple patents related to the White Armor cool roof granules product line. In March 2022, the jury returned a unanimous verdict for U.S. Silica on all counts, including willful infringement, and denied all of AKW's counterclaims. On March 29, 2023, the Court entered its Final Judgment. In addition to affirming the findings of the jury, the Court determined that both treble damages and a permanent injunction were appropriate, after observing that such remedies are generally available only for "egregious cases of culpable behavior."

06:58 EDT EU passenger car registrations up 28.8% in March - In March, the EU car market recorded a "significant" 28.8% increase in passenger car registrations, surpassing more than a million units at 1,087,939, reported the ACEA. "All the bloc's largest markets saw double-digit growth last month, with Spain and Italy in the lead," the group announced. Publicly traded automakers include Ford (F), General Motors (GM), Honda (HMC), Mercedes-Benz Group (DDAIF), Nissan (NSANY), Stellantis (STLA), Tesla (TSLA), Toyota (TM) and Volkswagen (VWAGY). Reference Link

06:52 EDT Chemours and TC Energy join to develop electrolysis-based hydrogen facilities - The Chemours (CC) and TC Energy (TRP) have executed a memorandum of understanding, or MOU, for the potential development of two electrolysis-based hydrogen production facilities at or near Chemours' Washington Works and Belle manufacturing sites in West Virginia. The MOU supports the companies' participation in and goals of the Appalachian Regional Clean Hydrogen Hub, or ARCH2, in West Virginia. The agreement covers the companies' interest in developing, constructing, and operating clean hydrogen production facilities and associated infrastructure. The proposed development includes using established proton exchange membrane, or PEM, electrolysers manufactured in America and utilizing Chemours' NafionTM ion exchange membranes. Under the terms of the MOU, a non-binding off-take agreement for hydrogen produced by the project would be executed, supporting the facility demands of Chemours. Additionally, hydrogen produced in excess of the off-take agreement would be stored and available for loading and shipment to nearby merchant users.

06:48 EDT U.S. Bancorp says 'on track' for Union Bank conversion over Memorial Day weekend

06:42 EDT Vista Gold releases final report of the Mineral Development Taskforce - Vista Gold reported the Northern Territory Government has released the final report of the Mineral Development Taskforce. The Report outlines a series of recommendations and actions to increase and enhance the competitiveness of the Northern Territory as an investment destination and to position the NT to achieve its economic growth targets by 2030. Frederick H. Earnest, President and CEO, stated: "The Report includes recommendations that will improve the NT's position as a leading destination for mining investment. As these recommendations are implemented, we expect the Company's Mt Todd gold project to benefit in several ways. "Most notably, the Report emphasizes the importance of updating the current royalties regime to make it more competitive and developing local skills to support the mining industry. This potentially means moving to a simpler ad valorum royalty structure and aligning the royalty rate more closely with other Tier 1 mining jurisdictions where rates typically range from 2.5%-5%. This represents a very meaningful opportunity for improved project economics and earlier shareholder returns at Mt Todd, where our 2022 feasibility study included NT royalties equivalent to a 7%-9% ad valorum rate, depending on the gold price and other assumptions. Skills development will also be an important benefit given that we support the use of a local work force at Mt Todd over more traditional fly-in/fly-out approaches common elsewhere in Australia."

06:32 EDT Citizens Financial reports Q1 net interest margin, FTE 3.3% vs. 2.75% last year

06:16 EDT General Motors venture arm invests in Nanoramic Laboratories - Nanoramic Laboratories announced that GM Ventures, the venture capital arm of General Motors, has made a strategic investment in a energy storage and advanced materials company, Nanoramic. The collaboration focuses on joint development and application of Nanoramic's proprietary Neocarbonix at the Core electrode technology for EV lithium-ion batteries, which targets improvements in EV battery cost, efficiency, and sustainability. Nanoramic's Neocarbonix at the Core is an electrode technology platform for cathode and anode designed for high-throughput manufacturing free of N-methyl-2-pyrrolidone solvent, enabling batteries with lower cost per kilowatt-hour and excellent performance. Neocarbonix achieves this by replacing conventional binder systems with a 3D nanocarbon mesh. This eliminates polyvinylidene fluoride (PVDF) binders from the cathode and the related need for NMP solvent in the manufacturing process. When applied to anode, Neocarbonix enables long-cycle-life silicon anodes using low-cost active materials.

06:12 EDT KBR signs joint development agreement with ISU Chemical for Li2S - KBR announced that it has signed a joint development agreement with ISU Chemical for the design of a commercial scale lithium sulfide, or Li2S, unit for next generation battery technology. Under the terms of the agreement, KBR will be the exclusive licensor of this technology. Lithium sulfide is used in the production of all-solid-state batteries, which in addition to being inherently safer and more efficient than conventional lithium-ion batteries, store more power.

06:03 EDT Block launchs Tap to Pay on Android - Square launched Tap to Pay on Android for sellers across the U.S., Australia, Ireland, France, Spain, and the United Kingdom. The new technology empowers sellers to securely accept contactless payments with a compatible Android device, and at no additional cost. With Tap to Pay on Android, Square is making it even easier for new sellers and established businesses to conduct in-person commerce. Using a compatible Android device, a seller simply opens the Square Point of Sale, Square Appointments, Square for Restaurants, or Square Invoices app, enters the sale, and presents their smartphone to the customer. From there, the buyer will see the total they owe along with the familiar contactless payments symbol, and can choose to complete the payment with a contactless credit or debit card, or a digital wallet such as Google Pay. Square is part of Block.

05:14 EDT Sherwin-Williams to divest China paint business to Akzo Nobel N.V. - Sherwin-Williams announced it has signed a purchase agreement with global coatings company Akzo Nobel N.V. to divest its China architectural paint business. The business manufactures and sells decorative paints under the Huarun brand name in China, has annual revenue of approximately $100M USD and employs approximately 300 people. The transaction is expected to close in the second half of 2023, pending customary regulatory approvals.

05:10 EDT NWTN Inc. signs memorandum of understanding with Elfaba Investment and Advisory - NWTN Inc. announced that it signed a memorandum of understanding with Elfaba Investment and Advisory for the sales and purchase of products of NWTN and Rabdan brands across more than seven countries. The MOU stipulates that NWTN will authorize Elfaba as the NWTN and Rabdan brand distributor for a period of five years, enabling the sale of NWTN and Rabdan vehicles, parts, and accessories together with the provision of after sales services. The MOU also stipulates that Elfaba will aim for sales of up to 5,000 vehicles. A definitive agreement is targeted to be signed by the end of April. Rabdan is a NWTN brand of intelligent new energy vehicles and encompasses a full range of intelligent new energy passenger vehicle products from extended range to pure electric technology solutions.